Researchers from China’s Peking University have developed a new
gene-editing technology — and they think it shows promise as a CRISPR
alternative for fighting human diseases.
According to a paper published on Monday in the journal Nature Biotechnology,
this new technology, LEAPER, which stands for “leveraging endogenous
ADAR for programmable editing of RNA,” works similarly to CRISPR-Cas13, targeting RNA molecules as opposed to DNA like the well-known CRISPR-Cas9.
But
while CRISPR-Cas13 relies on both a guide RNA and the Cas13 enzyme to
make its edits to RNA, the LEAPER system needs just one component known
as an arRNA.
Click for more